Contax's Five & Dime and a Couple of $$ too Investment Fund!

[TechKim]

Could $0.02 cent PLRS become a $5 stock?
PLURISTEM LIFE SYS (OTC BB:PLRS.OB)

A dollar to Five? here are three stocks in stem cell line.
ASTM, STEM and VIAC as examples.
AASTROM BIOSCIENCE (NasdaqCM:ASTM) $1.37
STEMCELLS INC (NasdaqGM:STEM) $2.69
VIACELL, INC. (NasdaqGM:VIAC) $5.20

http://finance.yahoo.com/q?s=ASTM,STEM,VIAC,PLRS.OB&d=s
============================================================
PLRS has the funding for research as they are umbilical/placenta stem cell.
===================================================
Call PLRS stock pot luck if you want!
Read the letter from the borrowed post from the STEM message board. The government is not allowing stem cell research to fade away!


--------------------------------------------------------------------------------------------------------------------------------
Borrowed from STEM message board on Yahoo.
http://messages.finance.yahoo.com/Healthcare/Biotechnology_and_Drugs/threadview?m=tm&bn=23129&am....

Here is a copy of a letter that my senator sent to me today October 17, 2006. Congress is not going to let the stem cell issue drop. Companies like STEM will provide treatment to help millions of sick Americans.

Dear XXXXXXXXXX:

Since you have contacted me in the past in support of federal funding for stem cell research, I wanted to update you on the status of this issue as the 109th Congress draws to a close.

The House of Representatives passed the Stem Cell Research Enhancement Act (H.R. 810) in May of 2005 by a substantial margin. Despite strong support in the Senate, the Majority leadership did not bring H.R. 810 to a vote in the Senate until July of 2006, at which point 66 Senators voted for
passage of the measure. I am a cosponsor of the Senate version of this bill and was encouraged by the strong vote in favor of the measure.

This bill sought to provide federal funding for stem cell research using only embryos that "would never be implanted in a woman and would otherwise be discarded." Such research has vast potential to improve treatments for dozens of serious illnesses, including multiple sclerosis, juvenile
diabetes, Lou Gehrig's disease, Parkinson's disease, and paralysis.

On July 19th of this year, the President used his power to override a majority of both houses of Congress and vetoed the Stem Cell Research Enhancement Act. It was the first veto of his presidency. Patient advocate groups and research institutions voiced their dismay that the
Administration would withhold funding for such a promising field of biomedical research. Though the House of representatives immediately took up the measure again, the bill fell short of the 290 votes needed to overcome the President's veto.

The potential to improve the lives of individuals who suffer from debilitating illness should not and cannot be ignored. That the President would choose this legislation for his first veto was a troubling message for the patients and families clinging to the hope of medical breakthroughs. I will keep working for the passage of the Stem Cell
Research Enhancement Act in the 110th Congress.

Sincerely,

Richard J. Durbin United States Senator